Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Low carbohydrate meals (other)
• Standard carbohydrate meals (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Endocrinology Research Center, Hvidovre University Hospital
  Hvidovre, Copenhagen, Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Pramlintide and glucagon (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Baylor College of Medicine
  Houston, Texas, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• ZP4207 (drug) — also listed as: analogue af human glucagon
• GlucaGen (drug) — also listed as: glucagon

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Profil Institut für Stoffwechselforschung GmbH
  Neuss, Germany
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Dual-hormone closed-loop (other)
• Insulin (drug)
• Glucagon (drug)
• Dexcom G4 Platinum glucose sensor (device)
• Accu Chek Combo insulin pump (device)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Institut de recherches cliniques de Montréal
  Montreal, Quebec, Canada
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Artificial Pancreas Control Software (device)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Legacy Good Samaritan Hospital
  Portland, Oregon, United States
  Site recruitment: Not reported
• Oregon Health and Science University
  Portland, Oregon, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Mixed Meal Tolerance Test (procedure)
• Glucagon Stimulation Test (procedure)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Children's Hospital Los Angeles
  Los Angeles, California, United States
  Site recruitment: Not reported
• University of California San Francisco
  San Francisco, California, United States
  Site recruitment: Not reported
• Stanford University Medical Center
  Stanford, California, United States
  Site recruitment: Not reported
• Barbara Davis Center for Childhood Diabetes, University of Colorado
  Denver, Colorado, United States
  Site recruitment: Not reported
• University of Florida
  Gainesville, Florida, United States
  Site recruitment: Not reported
• University of Miami School of Medicine
  Miami, Florida, United States
  Site recruitment: Not reported
• Riley Hospital for Children, Indiana University
  Indianapolis, Indiana, United States
  Site recruitment: Not reported
• Joslin Diabetes Center/ Children's Hospital Boston
  Boston, Massachusetts, United States
  Site recruitment: Not reported
• University of Minnesota
  Minneapolis, Minnesota, United States
  Site recruitment: Not reported
• Naomi Berrie Diabetes Center, Columbia University
  New York, New York, United States
  Site recruitment: Not reported
• Children's Hospital of Pittsburgh of UPMC
  Pittsburgh, Pennsylvania, United States
  Site recruitment: Not reported
• University of Texas Medical Center at Dallas
  Dallas, Texas, United States
  Site recruitment: Not reported
• Benaroya Research Institute
  Seattle, Washington, United States
  Site recruitment: Not reported
• Walter and Eliza Hall Institute of Medical Research
  Parkville, Victoria, Australia
  Site recruitment: Not reported
• University of Toronto
  Toronto, Ontario, Canada
  Site recruitment: Not reported
• University of Turku
  Turku, Finland
  Site recruitment: Not reported
• Vita-Salute San Raffaele University
  Milan, Italy
  Site recruitment: Not reported
• University of Bristol
  Bristol, United Kingdom
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Liraglutide (drug) — also listed as: LIR
• Placebo (drug) — also listed as: PLA

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Diabetes Unit E. Wolfson Hospital
  Holon, Tel Aviv, Israel
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Dipeptidyl-Peptidase IV Inhibitors (drug) — also listed as: DPP4 inhibitors
• Glucagon-Like Peptide 1 (drug) — also listed as: Liraglutide, Exenatide

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Mater Misericordiae University Hospital
  Dublin, Ireland
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Liraglutide (biological)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Mood Disorders Psychopharmacology Unit
  Toronto, Ontario, Canada
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Liraglutide (drug) — also listed as: Victoza, GLP-1 agonist
• Liraglutide Placebo (drug) — also listed as: Placebo

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Psychiatric Centre Rigshospitalet
  Copenhagen, København Ø, Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Liraglutide (drug) — also listed as: Trade name: Victoza, EV Product Code: SUB25238, Name of the Marketing Authorisation Holder: Novo Nordisk, Marketing Authorisation number: EU/1/09/529/001, ATC code: A10BX07, CAS number 204656-20-2
• Liraglutide - Placebo (drug) — also listed as: Placebo

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Leiden University Medical Center
  Leiden, Netherlands
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Lixisenatide (drug) — also listed as: Lyxumia
• Insulin glulisine (drug) — also listed as: Apidra

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• VU Universtiy Medical Center
  Amsterdam, Netherlands
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Liraglutide (drug) — also listed as: Victoza
• Duodenal-jejunal bypass liner - Endobarrier device (device) — also listed as: EC Certificate Full Quality Assurance System: Certificate US08/5323

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Department of Diabetes, City Hospital
  Birmingham, United Kingdom
  Site recruitment: Not reported
• Glasgow Royal Infirmary
  Glasgow, United Kingdom
  Site recruitment: Not reported
• Department of Diabetes, Guy's and St Thomas' Hospitals
  London, United Kingdom
  Site recruitment: Not reported
• Diabetes Research Group, King's College London
  London, United Kingdom
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Mixed meal test (other)
• Vildagliptin (drug)
• Sitagliptin (drug)
• Placebo (drug)
• Metformin (drug)
• Diet and exercise (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Diabeteszentrum Bad Lauterberg
  Bad Lauterberg im Harz, Lower Saxony, Germany
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• DPP-4 inhibitors (drug) — also listed as: incretin-based drugs, sitagliptin, vildagliptin, saxagliptin
• GLP-1 analogs (drug) — also listed as: incretin-based drugs, exenatide, liraglutide
• Insulins (drug) — also listed as: insulins and analogues for injection, fast-acting, insulins and analogues for injection, intermediate-acting, insulins and analogues for injection, long-acting, insulins and analogues for inhalation
• Biguanides (drug) — also listed as: oral hypoglycemic agent, phenformin, metformin, buformin
• Sulfonylureas (drug) — also listed as: oral hypoglycemic agent, glibenclamide, chlorpropamide, tolbutamide, glibornuride, tolazamide, carbutamide, glipizide, gliquidone, gliclazide, metahexamide, glisoxepide, glimepiride, acetohexamide, glymidine
• Thiazolidinediones (drug) — also listed as: oral hypoglycemic agent, troglitazone, rosiglitazone, pioglitazone
• Alpha-glucosidase inhibitors (drug) — also listed as: oral hypoglycemic agent, acarbose, miglitol, voglibose
• Meglitinides (drug) — also listed as: oral hypoglycemic agent, repaglinide, nateglinide

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Lady Davis Institute for Medical Research, Jewish General Hospital
  Montreal, Quebec, Canada
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Intranasal glucagon (drug)
• Intranasal placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

The registry does not list facilities in this record. This does not mean the study has no sites.

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• GLP-1 (7-36) amide (drug)
• Glibenclamide (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Papworth Hospital
  Cambridge, Cambridgeshire, United Kingdom
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Right Coronary Artery Percutaneous Coronary Intervention (procedure) — also listed as: Device - stent
• saline placebo infusion (other)
• GLP-1 Infusion (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Papworth Hospital NHS Foundation Turst
  Cambridge, Cambridgeshire, United Kingdom
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Linagliptin (drug)
• Placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Department of Endocrinology, PGIMER
  Chandigarh, Chandigarh, India
  Site recruitment: Recruiting